Inkemia IUCT platform is capable of designing, synthesizing and evaluating candidate molecules to interact with drug targets.
We have the work teams, the infrastructure, the know-how and extensive experience in:
- Design and chemical synthesis.
- Medicinal chemistry.
- High Throughput Experimentation.
- High Throughput Analysis.
- Structural elucidation and
- Search for Intellectual Property.
Likewise, our team has extensive experience in:
- Organic synthesis, biotechnology and biocatalysis processes through the use of own enzymes or with living microorganisms.
- Computational chemistry tools for in silico design of candidates.
- Specific know-how in scaling processes for the subsequent industrial manufacturing of the products.
Our activities include: scaffold design and modification, de novo structural design, scaffold and library route design, scaffold and building block synthesis, transformation of multi-step processes into one-step reactions, highly chemo-, regio- and stereo-selective processes, low-cost developments, proprietary processes...and many others.
In short, working with Inkemia offers:
- Flexibility: up to 4 complementary approaches for the synthesis of compounds.
- Added value: we not only provide the desired compounds but also the complete route required for subsequent pilot and industrial scale-up.
- Ease of producing any type of enzyme, native, recombinant or mutant.
- Extensive experience and knowledge in analysis and synthesis.
We also have a wide collection of compounds and hits in cancer and other diseases (viral, inflammatory, coagulation, etc.) available for licensing or co-development agreements.
1) Libraries of new nucleoside analogues for anticancer activity assays : through the HTB Platform, IUCT has a powerful technological tool to create collections of hundreds of new nucleoside analogues through the synergy offered by the coupling of biotechnological processes and organic synthesis tools.
There are currently around 500 compounds available for which information on their structure, purity, concentration and complete data sheet is provided in ChemFinder format.
These compounds can be provided individually, as a subset (filtered selection according to customer requirements), or as a global collection.
Additionally, preparation of selected structures based on the client's structural requirements is possible.
Advantages associated with its use
- Structural novelty for the vast majority of molecules in the collection.
- Compounds with characteristics compatible with drug requirements ( drug-like ).
- Possibility of identifying hits or lead compounds in R&D of new anticancer drugs.
- Possibility of identifying R&D hits in new pharmacological activities.
- Supply and scaling: it is possible to re-synthesize and scale the products up to 1-2 grams.
We also have hits for licensing or co-development agreements in several cancer indications: lung, breast, colon, liver, prostate, kidney, pancreas, lymphoma, leukemia and glioblastoma.
2) Library of new nucleoside analogues for antiviral activity assays: through the HTB platform, IUCT has a powerful technological tool to create libraries of new nucleoside analogues through the synergy offered by the coupling of biotechnological processes and multiple synthesis in parallel.
There are currently around 500 compounds available for which information on their structure, purity, concentration and complete data sheet is provided in ChemFinder format.
These compounds can be provided individually, as a subset (filtered selection according to customer requirements), or as a global collection.
Additionally, preparation of selected structures based on the client's structural requirements is possible.
Advantages associated with its use
- Structural novelty for the vast majority of molecules in the collection.
- Compounds with characteristics compatible with drug requirements ( drug-like ).
- Possibility of identifying hits or lead compounds in R&D of new antiviral drugs.
- Possibility of identifying R&D hits in new pharmacological activities.
- Supply and scaling: it is possible to re-synthesize and scale the products up to 1-2 grams.
3) Libraries of new sulfonamides as antagonists of receptors involved in inflammatory processes: The compounds have been designed as antagonists of bradykinin B 1 and B 2 receptors , involved in inflammatory processes that cause pain and inflammation, such as: in respiratory diseases (asthma, rhinitis), arthritis, pancreatitis, sepsis, etc.
There are currently about 200 compounds available for which information on their structure, purity, concentration and complete data sheet is provided in ChemFinder format.
These compounds can be provided individually, as a subset (filtered selection according to customer requirements), or as a global collection.
Additionally, preparation of selected structures based on the client's structural requirements is possible.
Advantages associated with its use
- Novedad estructural para la gran mayoría de las moléculas de la colección.
- Compuestos con características compatibles con los requerimientos de los fármacos (drug-like).
- Posibilidad de identificar hits o lead compounds en I+D de nuevos fármacos antiinflamatorios.
- Posibilidad de identificar hits en I+D en nuevas actividades farmacológicas.
- Desarrollo sintético robusto: en cualquier momento es posible re-sintetizar o escalar los productos; por tanto, su provisión está garantizada para las diferentes fases de desarrollo del candidato a fármaco.
4) Biblioteca de nuevas sulfonamidas para ensayos de anticoagulación:Los compuestos han sido diseñados como inhibidores de distintas proteínas implicadas en procesos de coagulación: Trombina (Factor FIIa), Factor X Activado (FXa), Factor de Coagulación VIIa, Tripsina, Factor de Coagulación IX, etc.
Actualmente hay disponibles unos 200 compuestos de los cuales se facilita información sobre su estructura, pureza, concentración y su ficha completa en formato ChemFinder.
Dichos compuestos se pueden facilitar de forma individual, como subgrupo (selección filtrada según los requerimientos del cliente), o como colección global.
Adicionalmente, es posible la preparación de estructuras seleccionadas basadas en requerimientos estructurales del cliente.
Ventajas asociadas a su uso
- Novedad estructural para la gran mayoría de las moléculas de la colección.
- Compuestos con características compatibles con los requerimientos de los fármacos (drug-like).
- Posibilidad de identificar hits o lead compounds en I+D de nuevos fármacos anticoagulantes.
- Posibilidad de identificar hits en I+D en nuevas actividades farmacológicas.
- Desarrollo sintético robusto: en cualquier momento es posible re-sintetizar o escalar los productos. Por tanto, su provisión está garantizada para las diferentes fases de desarrollo del candidato a fármaco.
5) Biblioteca de compuestos tropánicos: son compuestos con actividad sobre el Sistema Nervioso Central (SNC).
Actualmente hay disponibles unos 30 compuestos de los cuales se facilita información sobre su estructura, pureza, concentración y su ficha completa en formato ChemFinder.
Dichos compuestos se pueden facilitar de forma individual, como subgrupo (selección filtrada según los requerimientos del cliente), o como colección global.
Adicionalmente, es posible la preparación de estructuras seleccionadas basadas en requerimientos estructurales del cliente.
Ventajas asociadas a su uso
- Possibility of identifying hits or lead compounds in R&D of new drugs in CNS diseases related to a decrease in dopaminergic, serotonergic or noradrenergic activity (depression, anxiety, Parkinson's, Alzheimer's, migraine, panic attacks, narcolepsy, etc.) from compounds derived from a structure that has activity in this field.
- Very complex synthesis optimized.
We also have 3 hits with improved motor activity in a fly model of Parkinson's disease available for licensing or co-development agreements.
